NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge

A federal jury ruled that Eli Lilly & Co. breached the implied covenant of good faith and fair dealing with Nektar Therapeutics, awarding Nektar $90 million in damages. The jury rejected Nektar's claim that Lilly breached the license agreement's commercially reasonable efforts (CRE) obligation. Lilly plans to appeal, arguing no liability should have been imposed. The case highlights risks in biopharma licensing agreements.

Nektar Therapeutics (NKTR) won a $115 million lawsuit against Eli Lilly (LLY), resolving a multi-year overhang. The verdict, including interest, amounts to ~5% of NKTR's market cap. Despite the win, NKTR's stock fell over $200 million in market cap due to market volatility and rising yields. Cedar Grove Capital Management views this as a net positive for NKTR, removing a long-standing uncertainty.

H.C. Wainwright reiterated a Buy rating and $185 price target on Nektar Therapeutics (NKTR) after positive alopecia data. NKTR shares fell 22.4% on Oct 1, despite analysts' bullish consensus. NKTR reported a smaller-than-expected Q2 2026 loss but missed revenue expectations. NKTR won a $90M verdict against Eli Lilly.

HC Wainwright & Co. maintained a Buy rating on Nektar Therapeutics with a $185 price target, suggesting a 293.7% upside from the Oct 1 close of $46.99. The firm cited strong Phase 2b data for rezpeg and an undervalued stock as reasons for the recommendation.

Nektar Therapeutics (NKTR) shares fell after mid-stage trial data for its hair loss drug rezpegaldesleukin was released, showing results from the REZOLVE-AA trial. The stock neared an eight-month low. The drug is being tested as a late-line treatment option.

Nektar Therapeutics (NKTR) shares fell despite positive trial data for its alopecia drug, rezpegaldesleukin. The study showed 29% (low dose) and 31% (high dose) of patients benefited for six months without treatment. The drug is also being tested for eczema and diabetes.